Clinical Trial Update: Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update discusses an ongoing Phase 1/2 study of TQB2303 for aggressive CD20-positive Non-Hodgkin lymphoma, with the current status not disclo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• TQB2303

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Non-hodgkin's Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN